Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 25, 2026
DataAggregated Company Financials
Companies21
  • 7D1.8%
  • 3M12.2%
  • 1Y-31.3%
  • YTD16.7%

The Healthcare industry is up 1.8% in the last week, with Novo Nordisk up 3.2%. In the same time, Coloplast was down 6.2%. In contrast, the industry has lost 31% in the last 12 months. Earnings are forecast to grow by 4.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 25 Jan 2026DKK 2.3tDKK 453.5bDKK 136.8b18.4x16.7x5x
Tue, 23 Dec 2025DKK 1.8tDKK 453.7bDKK 136.9b16.9x13.5x4.1x
Thu, 20 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b16.9x13.7x4.1x
Sat, 18 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Mon, 15 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Wed, 13 Aug 2025DKK 1.9tDKK 434.7bDKK 132.4b29x14.1x4.3x
Fri, 11 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.3x19.9x5.9x
Sun, 08 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Tue, 06 May 2025DKK 2.5tDKK 409.3bDKK 121.3b22.3x20.7x6.1x
Thu, 03 Apr 2025DKK 2.5tDKK 409.5bDKK 121.3b23.3x20.8x6.2x
Sat, 01 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Mon, 27 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Wed, 25 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.7x29.5x8.5x
Fri, 22 Nov 2024DKK 3.8tDKK 387.4bDKK 111.3b31.2x33.8x9.7x
Sun, 20 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Tue, 17 Sep 2024DKK 4.7tDKK 371.9bDKK 107.1b36.5x44x12.7x
Thu, 15 Aug 2024DKK 4.6tDKK 370.3bDKK 106.9b36.8x43.4x12.5x
Sat, 13 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Mon, 10 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Wed, 08 May 2024DKK 4.5tDKK 355.3bDKK 106.5b35x42.3x12.7x
Fri, 05 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b38x44.4x13x
Sun, 03 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Tue, 30 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.7x42.7x12x
Thu, 28 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b33.1x40x11.2x
Sat, 25 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Mon, 23 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Wed, 20 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b35.4x41.7x11.2x
Fri, 18 Aug 2023DKK 3.4tDKK 302.9bDKK 81.1b37.7x41.6x11.1x
Sun, 16 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.6x10.1x
Tue, 13 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.1x40x10.5x
Thu, 11 May 2023DKK 3.1tDKK 285.5bDKK 74.7b41x42.1x11x
Sat, 08 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Mon, 06 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.4x40.7x9.6x
Wed, 01 Feb 2023DKK 2.7tDKK 275.9bDKK 66.3b37.1x40.2x9.7x
Price to Earnings Ratio

40.2x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 275.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.7x which is lower than its 3-year average PE of 33.5x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.0065%
Healthcare1.77%
Healthcare Services4.00%
Pharma2.93%
Biotech-1.66%
Life Sciences-2.99%
Medical Equipment-4.62%
Healthtech-5.05%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 273x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 401.353.2%
+DKK 55.3b		-35.5%PE17.2x
ZEAL Zealand PharmaDKK 426.001.5%
+DKK 457.8m		-45.3%PE4.6x
SMSMED Scandinavian Medical SolutionsDKK 3.904.0%
+DKK 4.2m		-29.3%PE4170.9x
MONSO MonsensoDKK 0.1614.7%
+DKK 1.5m		-56.2%PS1.1x

Latest News

SMSMED
DKK 3.90
Scandinavian Medical Solutions
7D
4.0%
1Y
-29.3%
COLO B
DKK 541.80
Coloplast
7D
-6.2%
1Y
-33.0%

COLO B: Dividend Reliability And Premium P/E Will Support Future Upside

Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.
ALK B
DKK 219.40
ALK-Abelló
7D
-2.1%
1Y
41.9%

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?
NOVO B
DKK 401.35
Novo Nordisk
7D
3.2%
1Y
-35.5%

NOVO B: Wegovy Pill Launch And Execution Discipline Will Support Future Upside

Analysts have reduced their fair value estimate for Novo Nordisk to €540 from €612. They cite more moderate assumptions for revenue growth and profit margins, along with a higher discount rate and a slightly higher expected future P/E multiple.
DEMANT
DKK 230.00
Demant
7D
-1.3%
1Y
-19.6%

An Intrinsic Calculation For Demant A/S (CPH:DEMANT) Suggests It's 24% Undervalued

Jan 22
An Intrinsic Calculation For Demant A/S (CPH:DEMANT) Suggests It's 24% Undervalued
GMAB
DKK 2,130.00
Genmab
7D
-2.5%
1Y
41.7%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
HLUN B
DKK 45.56
H. Lundbeck
7D
-2.1%
1Y
10.1%

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
AMBU B
DKK 87.05
Ambu
7D
-4.6%
1Y
-35.7%

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).
EMBLA
DKK 31.90
Embla Medical hf
7D
-2.1%
1Y
-6.2%

EMBLA: Ukraine Program And Buybacks Will Support Future Margin Stability

Analysts have kept their fair value estimate for Embla Medical hf unchanged at €34.00. They have updated assumptions around discount rate, revenue growth, profit margins and future P/E to reflect a slightly different balance of risk and profitability in their models.
ZEAL
DKK 426.00
Zealand Pharma
7D
1.5%
1Y
-45.3%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
CHEMM
DKK 684.00
ChemoMetec
7D
-3.9%
1Y
37.4%
MONSO
DKK 0.16
Monsenso
7D
14.7%
1Y
-56.2%